Last $3.62 USD
Change Today -0.08 / -2.16%
Volume 393.0K
SGYP On Other Exchanges
Symbol
Exchange
NASDAQ GS
NASDAQ CM
As of 8:10 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

synergy pharmaceuticals inc (SGYP) Snapshot

Open
$3.69
Previous Close
$3.70
Day High
$3.70
Day Low
$3.61
52 Week High
03/4/14 - $6.70
52 Week Low
05/9/14 - $3.39
Market Cap
343.2M
Average Volume 10 Days
587.6K
EPS TTM
$-0.83
Shares Outstanding
94.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNERGY PHARMACEUTICALS INC (SGYP)

synergy pharmaceuticals inc (SGYP) Related Businessweek News

No Related Businessweek News Found

synergy pharmaceuticals inc (SGYP) Details

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase II clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

25 Employees
Last Reported Date: 03/17/14

synergy pharmaceuticals inc (SGYP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $680.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $279.9K
Chief Scientific Officer
Total Annual Compensation: $368.5K
Compensation as of Fiscal Year 2013.

synergy pharmaceuticals inc (SGYP) Key Developments

Synergy Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Synergy Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's net loss was $25.920 million or $0.28 per basic and diluted share, as compared to a net loss of $11.858 million or $0.11 per basic and diluted share a year ago. Loss from operations was $26.758 million compared with $11.858 million a year ago. For the six months, the company's net loss was $42.145 million or $0.45 per basic and diluted share, as compared to a net loss of $28.736 million or $0.36 per basic and diluted share a year ago. Loss from operations was $43.235 million compared with $29.480 million a year ago.

Synergy Pharmaceuticals, Inc. Completes Patient Enrollment for its SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation

Synergy Pharmaceuticals, Inc. announced that it has successfully completed patient enrollment for its phase 2 trial of SP-333, Synergy's next-generation uroguanylin analog, in patients with opioid-induced constipation (OIC). The multi-center, randomized, double-blind clinical trial is designed to compare a 4-week dose-ranging regimen of once-daily oral SP-333 (1.0 mg, 3.0 mg and 6.0 mg) against placebo in patients taking opioid analgesics for chronic, non-cancer pain for at least three months. The study will evaluate approximately 260 patients with OIC who have less than 3 spontaneous bowel movements (SBMs) per week and who experience constipation related symptoms. The primary endpoint of the study is mean change from baseline in the number of SBMs during Week 4 of the Treatment Period.

Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

Synergy Pharmaceuticals Inc. announced that it has reached the halfway mark for total enrollment in the first pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation (CIC). The trial is currently being conducted at 180 sites and has randomized approximately 675 CIC patients. This is the first of two ongoing pivotal phase 3 trials designed to confirm the efficacy and safety of both 3.0 mg and 6.0 mg plecanatide doses versus placebo in CIC patients. Synergy announced the initiation of its second phase 3 CIC trial in April 2014. The company plans to release top-line data from the first phase 3 CIC trial in the second quarter of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGYP:US $3.62 USD -0.08

SGYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.59 EUR +0.38
Ironwood Pharmaceuticals Inc $13.11 USD -0.08
Sucampo Pharmaceuticals Inc $6.98 USD -0.16
View Industry Companies
 

Industry Analysis

SGYP

Industry Average

Valuation SGYP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNERGY PHARMACEUTICALS INC, please visit www.synergypharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.